ipamorelin injection frequency CJC-1295 + ipamorelin injection frequency CJC 1295

DOI: 10.1186/s13287-020-01803-7 42

Darabian, S

Pourzamania, H., Darvishmotevalli, M., Akhyari, S

4432-A RONA-APOC3, AN INVESTIGATIONAL RNAi-MEDIATED APOLIPOPROTEIN C3 GENE SILENCING, DEMONSTRATES SIGNIFICANT EFFICACY AND GOOD SAFETY IN PRECLINICAL MODELS Xujie LIU, Guoqing Cai, Guofeng Meng, Hongli Guo, Xiaoyan Yang, Xinxin Xu, Cong Huang, Junkai Liu, Hao Zou, Jinyu Huang, Jianwu Fang and Stella Shi, Rona Therapeutics Background: Human genetic analysis has identified that individuals with loss-of-function mutations in apolipoprotein C3 (APOC3) have lower levels of serum triglycerides (TGs) and decreased risks of cardiovascular disease (CVD)